ADOCIA announced the appointment of three independent Directors to the appointment of three independent Directors to the Board of Directors. The appointees: Claudia Mitchell, Katherine Bowdish and Stéphane Boissel joined the board as of May 21, 2021. In parallel, Dominique Takizawa has decided to resign after ten years of service on the board. Dr. Claudia Mitchell, Senior VP, Head of Portfolio Strategy, at Astellas Pharma, has a thorough grounding in the biotech sector. Prior to joining Astellas in 2019, she co-founded Universal Cell and served as CEO until Astellas acquired the company only four years later for over $100 million. Dr. Katherine Bowdish, President & CEO of PIC Therapeutics, is a highly experienced professional in the life science sector having co-found several companies working on biological therapies. Stéphane Boissel, Chairman and CEO of SparingVision, is a seasoned biotech professional with over twenty-five years of leadership experience across corporate finance strategy and business development in internationally focused companies.